What is Envarsus (extended‑release tacrolimus)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is Envarsus XR?

Envarsus XR is an extended-release, once-daily tacrolimus formulation that uses MeltDose technology to enhance drug dissolution and bioavailability, approved for preventing organ rejection in kidney transplant recipients. 1

Formulation and Mechanism

Envarsus XR (also called LCP-tacrolimus or tacrolimus prolonged-release) is fundamentally different from other tacrolimus formulations:

  • Active ingredient: Tacrolimus, a calcineurin-inhibitor immunosuppressant that binds to intracellular protein FKBP-12, ultimately inhibiting T-lymphocyte activation and proliferation 1

  • MeltDose technology: Creates a solid solution that enhances dissolution of this poorly water-soluble drug, resulting in approximately 20-30% higher bioavailability compared to immediate-release tacrolimus 2, 3

  • Extended-release profile: Provides more consistent drug exposure with reduced peak-trough fluctuation and longer time to maximum concentration 3

Clinical Indications

FDA-approved use: Prevention of organ rejection in kidney transplant recipients, used in combination with other immunosuppressants 1

The formulation is available as extended-release tablets in 0.75 mg, 1 mg, and 4 mg strengths 1.

Key Pharmacokinetic Advantages

Dose requirements: Due to enhanced bioavailability, Envarsus XR requires approximately 30% lower doses than immediate-release tacrolimus to achieve equivalent therapeutic trough concentrations 4, 2

Conversion ratios:

  • From immediate-release tacrolimus: 80% of total daily dose for most patients 1
  • African-American patients specifically: 80% conversion factor is appropriate 1
  • From Advagraf (another extended-release formulation): 30% dose reduction achieves therapeutic levels 4

Important Clinical Considerations

Serious Risks (Black Box Warnings)

  • Increased cancer risk: Including skin cancer and lymphoma 1
  • Increased infection risk: Immunosuppression lowers ability to fight infections; serious infections can be fatal 1
  • Requires experienced transplant physicians: Should only be prescribed by healthcare providers experienced in immunosuppressive therapy 1

Monitoring Requirements

Therapeutic drug monitoring is essential due to tacrolimus's narrow therapeutic index. Target trough levels vary by:

  • Time post-transplant
  • Combination with other immunosuppressants
  • Patient-specific factors 5, 1

Recent guidelines recommend lower tacrolimus trough targets than historically used (6-10 ng/mL first month, then 4-8 ng/mL) to preserve renal function without increasing rejection 5.

Special Populations

African-American and Hispanic patients: At increased risk for new-onset diabetes after transplant; requires blood glucose monitoring 1

Hepatic impairment: Patients with moderate hepatic impairment require close monitoring of whole blood trough concentrations 1

Pregnancy: Can harm the fetus; effective contraception required for both males and females during treatment. Pregnancy registry available at 1-877-955-6877 1

Practical Advantages

Once-daily dosing potentially improves medication adherence compared to twice-daily immediate-release formulations, though long-term adherence data are still emerging 6, 3.

Important: Envarsus XR is not interchangeable with other tacrolimus formulations (immediate-release capsules, other extended-release formulations, or oral suspension) without dose adjustment and monitoring 1.

References

6
Research

Extended release once a day tacrolimus.

Current opinion in organ transplantation, 2015

Related Questions

Is it safe to take Envarsus XR (tacrolimus extended-release) 4 mg once daily together with three 1 mg tablets of Envarsus XR daily?
A patient is currently taking a total of 7 mg of Envarsus (tacrolimus) once daily; how should the dose be adjusted based on his tacrolimus trough concentration?
Is it appropriate to combine tacrolimus Envarsus XR 4 mg once daily with tacrolimus immediate‑release Envarsus 1 mg three times daily?
I have an inflammatory rash on my body that did not respond to tacrolimus; which steroid should I use and what dosage?
Which medications can increase plasma tacrolimus concentrations?
What is the standard starting dose of Envarsus XR (extended‑release tacrolimus) when used with mycophenolate mofetil 500 mg twice daily and a corticosteroid in a transplant patient?
Does a prior severe reaction to semaglutide affect the safety or administration of the 20‑valent pneumococcal conjugate vaccine (Prevnar 20)?
What are the contraindications for phentermine?
What is the recommended dosing schedule for primidone in essential tremor and what are its common and serious side effects?
Is cephalexin appropriate for treating a pediatric Proteus mirabilis urinary tract infection?
Do ubiquinone (oxidized Coenzyme Q10) and ubiquinol (reduced Coenzyme Q10) increase mitochondrial ATP production and improve mitochondrial health?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.